Bibliographic information
GuidelineWHO guidelines on tuberculosis infection prevention and control: 2019 update
Year of Publication2019
Issuing InstitutionWHO
Recommendation
New
In multidrug-resistant tuberculosis or rifampicin-resistant tuberculosis (MDR/RR-TB) patients on longer regimens that contain amikacin or streptomycin, an intensive phase of 6–7 months is suggested for most patients; the duration may be modified according to the patient’s response to therapy
Recommended in favor
Conditional
Certainty of evidence
Very low
Notes and Remarks
WHO standards for the adequate number and appropriate position of hand hygiene facilities should be implemented in all health care facilities.